

## Original Article

# The association of pre-operative anaemia with survival after orthotopic liver transplantation

P. Lichtenegger,<sup>1</sup> J. Schiefer,<sup>2</sup> A. Graf,<sup>3</sup> G. Berlakovich,<sup>4</sup> P. Faybik,<sup>5</sup> D. M. Baron<sup>5</sup> and J. Baron-Stefaniak<sup>2</sup>

1 Specialty Registrar, 2 Consultant, 5 Associate Professor, Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, 3 Associate Professor, Section for Medical Statistics, Centre for Medical Statistics, Informatics, and Intelligent Systems, 4 Head, Division of Transplantation, Department of Surgery, Medical University of Vienna, Vienna, Austria

## Summary

Anaemia is common in patients with end-stage liver disease. Pre-operative anaemia is associated with greater mortality after major surgery. We analysed the association of pre-operative anaemia (World Health Organization classification) with survival and complications after orthotopic liver transplantation using Cox and logistic regression models. We included patients undergoing their first orthotopic liver transplantation between 2004 and 2016. Out of 599 included patients, 455 (76%) were anaemic before transplantation. Pre-operative anaemia was not associated with the survival of 485/599 (81%) patients to 1 year after liver transplantation, OR (95%CI) 1.04 (0.64–1.68),  $p = 0.88$ . Pre-operative anaemia was associated with higher rates of intra-operative blood transfusions and acute postoperative kidney injury on multivariable analysis, OR (95%CI) 1.70 (0.82–2.59) and 1.72 (1.11–2.67), respectively,  $p < 0.001$  for both. Postoperative renal replacement therapy was associated with pre-operative anaemia on univariate analysis, OR (95%CI) 1.87 (1.11–3.15),  $p = 0.018$ .

Correspondence to: D. M. Baron

Email: david.baron@meduniwien.ac.at

Accepted: 15 October 2019

Keywords: end-stage liver disease; morbidity; mortality; orthotopic liver transplantation; outcome; pre-operative anaemia; transfusion

## Introduction

Orthotopic liver transplantation can cure patients suffering from acute or chronic liver failure, the outcome of which is associated with several patient variables, such as age, diabetes mellitus, postoperative acute kidney injury and peritonitis [1–5]. Survival to one postoperative year is about 80% [6].

Pre-operative anaemia is present in about one-third of patients who undergo major surgery and it is associated with subsequent morbidity and mortality [7, 8]. The incidence of anaemia before orthotopic liver transplantation is as high as 75%, but it is uncertain whether it is associated with outcome [6, 9, 10].

Packed red blood cells are often transfused to correct anaemia, yet transfusion is associated with adverse outcomes and may cause increased morbidity and mortality

after cardiac, orthopaedic and abdominal surgery [11–16]. Transfusion is also associated with adverse outcomes after liver transplantation [2, 17].

Our primary aim was to evaluate the association of anaemia before orthotopic liver transplantation with survival to 1 year and secondarily survival to the end of follow-up. We were also interested in the associations of peri-operative variables, including blood transfusion, with these outcomes and their interactions with pre-operative anaemia.

## Methods

The ethics committee of the Medical University of Vienna approved this study. We studied patients admitted to our hospital for orthotopic liver transplantation between January 2004 and December 2016. We did not include

children (< 18 years), patients having concurrent lung or kidney transplantation, and patients with missing haemoglobin values within 24 pre-operative hours.

Orthotopic liver transplantation was performed under general anaesthesia, with caval replacement without the routine of veno-venous bypass. Blood group and physiological body-to-weight ratio were matched between donor grafts and transplant recipients. All patients were admitted to an intensive care unit (ICU) postoperatively. Immunosuppressive therapy was started with intravenous dexamethasone 40 mg before graft reperfusion. For the first five postoperative days patients received a reduced dexamethasone dose every 24 h, followed by a daily dose of 4 mg for 3 months (and longer for patients with autoimmune disease). Anti-thymocyte globulin 2.5 mg.kg<sup>-1</sup> was started on arrival in the ICU and continued for 3 days, after which immunosuppressive therapy was continued with low-dose tacrolimus or cyclosporin A at target concentrations of 6–8 ng.ml<sup>-1</sup> and 130–150 ng.ml<sup>-1</sup>, respectively.

We determined the association of WHO-defined pre-operative anaemia (< 13 g.dl<sup>-1</sup> for men and < 12 g.dl<sup>-1</sup> for women) with 1-year survival. We performed secondary analyses of the association of the severity of anaemia in men and women with survival, categorised as mild (11–13 g.dl<sup>-1</sup> and 10–12 g.dl<sup>-1</sup>, respectively), moderate (8–11 g.dl<sup>-1</sup> and 8–10 g.dl<sup>-1</sup>, respectively) or severe (< 8 g.dl<sup>-1</sup>) [18]. The secondary outcome was survival to the end of 2017.

We assessed the associations of pre-operative variables other than anaemia with outcomes such as age; sex; body mass index; model for end-stage liver disease (MELD) score; coronary artery disease; chronic obstructive pulmonary disease; diabetes mellitus; and pre-operative hospitalisation. We defined coronary artery disease as the presence of coronary atherosclerosis (> 50% stenosis of a coronary artery), or previous percutaneous coronary intervention. We defined pre-operative hospitalisation as inpatient treatment for at least 3 days before liver transplantation, or repeated

**Table 1** Characteristics of 599 patients who had orthotopic liver transplantation, categorised by pre-operative anaemia. Values are mean (SD), median (IQR [range]) or number (proportion).

Characteristic	All patients (n = 599)	Anaemic		p value
		No (n = 144)	Yes (n = 455)	
Pre-operative				
Age; years	53 (10)	55 (8)	53 (11)	0.001
Sex; male	434 (72%)	101 (70%)	333 (73%)	0.54
Body mass index; kg m <sup>-2</sup>	26.1 (4.4)	26.4 (4.2)	26 (4.5)	0.42
MELD score	16 (7)	13 (6)	17 (7)	< 0.001
Coronary artery disease	20 (3%)	6 (4%)	14 (3%)	0.52
COPD	38 (6%)	10 (7%)	28 (6%)	0.89
Diabetes mellitus	135 (23%)	42 (29%)	93 (20%)	0.038
Hospitalisation	60 (10%)	6 (4%)	54 (12%)	0.011
Intra-operative				
Cold ischaemia time; min	471 (139)	482 (147)	468 (136)	0.32
Warm ischaemia time; min	79 (19)	77 (18)	79 (20)	0.24
Transfusion				
Packed red blood cells	2 (0–5 [0–40])	0 (0–2 [0–19])	3 (1–6 [0–40])	< 0.001
Fresh frozen plasma	7 (4–12 [0–62])	5 (0–9 [0–30])	8 (4–12 [0–62])	< 0.001
Platelets	0 (0–1 [0–9])	0 (0–0 [0–3])	0 (0–1 [0–9])	0.020
Postoperative				
Surgical complications	113 (19%)	21 (15%)	92 (20%)	0.18
Early allograft dysfunction	138 (23%)	27 (19%)	111 (24%)	0.20
Acute kidney injury	412 (69%)	82 (57%)	330 (73%)	< 0.001
Renal replacement therapy	126 (21%)	20 (14%)	106 (23%)	0.023
Length of ICU stay; days	6 (4–11 [0–98])	5 (4–9 [1–90])	7 (4–12 [0–98])	< 0.001
Length of hospital stay; days	19 (14–28 [6–196])	15 (13–25 [6–118])	20 (14–30 [9–196])	0.002

COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; MELD, model for end-stage liver disease.


hospital admissions within 1 month before liver transplantation. We also analysed intra-operative and postoperative variables: cold ischaemia time; warm ischaemia time; and transfused blood products – packed red blood cells, fresh frozen plasma and platelets; surgical revision; early allograft dysfunction; acute kidney injury; and renal replacement therapy. We defined surgical revision as surgery for bleeding, vascular or biliary duct stenosis, biliary duct leak or intra-abdominal haematoma and peritonitis within one postoperative month. We defined early allograft dysfunction as at least one of serum bilirubin concentration  $\geq 10 \text{ mg.dl}^{-1}$  or international normalised ratio  $\geq 1.6$  7 days after surgery; or serum aminotransferase concentration  $> 2000 \text{ IU.ml}^{-1}$  within one postoperative week [19]. We defined acute kidney injury with standard criteria [20]. We categorised patients by whether they had renal replacement therapy within one postoperative week.

We did not calculate sample size for this retrospective study. We used two-sample t-test or Wilcoxon rank-sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables to compare patients with and without anaemia. We analysed 1-year survival using univariable and multivariable logistic regression and overall survival using univariable and multivariable Cox proportional hazard regression models. We used

Schoenfeld residuals to test for violation of proportional hazards. We used accelerated failure time models for sensitivity analysis. We used cubic splines to test for non-linear associations of continuous variables with outcome. We tested for interactions between variables. We used a stepwise selection and retention method for multivariable model selection, adding and removing variables at  $p < 0.05$ , so that the final model only included variables with  $p < 0.05$ . We used univariable and multivariable logistic regression models for the association of anaemia with postoperative acute kidney injury, renal replacement therapy, early allograft dysfunction and surgical complications and linear regression models for the association of anaemia and packed red blood cell transfusion. We used R, release 3.3.3 [21] and SAS 9.4 for the statistical analyses. We considered  $p < 0.05$  to be statistically significant.

## Results

We studied 599/659 patients, most of whom were anaemic before orthotopic liver transplantation (Table 1 and Table S1). The mean (SD) pre-operative haemoglobin concentration was  $13.8 (1.1) \text{ g.dl}^{-1}$  for 144 patients who were not anaemic and  $10.2 (1.5) \text{ g.dl}^{-1}$  for 455 anaemic patients. Anaemic patients were younger but with worse liver disease, for which they were more



**Figure 1** Survival after orthotopic liver transplantation of 599 patients, categorised by pre-operative haemoglobin concentration as not anaemic in 144 patients (green line); or anaemic in 455 patients (red line). Corresponding 95% CIs are shown as green or red areas, respectively. There were no statistically significant differences during the first year or for overall survival,  $p = 0.88$  and  $p = 0.20$ , respectively.

often hospitalised, and they were more likely to have diabetes (Table 1).

There were 114/599 (19%) deaths in the first postoperative year from infection in 36 (32%); bleeding in 15 (13%); graft failure in 11 (10%); multi-organ failure in 9 (8%); cardiovascular events in 6 (5%); cancer in 5 (4%); surgical complications in 5 (4%); disease recurrence in 3 (3%); respiratory failure in 3 (3%); and unknown in 19 (17%). The median (IQR [range]) follow-up was 4 (1–9 [0–15]) years, and the median survival (95%CI) was 11 (8–13) years. There were 235 deaths during follow-up from infection in 51 (22%); bleeding in 20 (9%); graft failure in 18 (8%); multi-organ failure in 15 (6%); cardiovascular events in 12 (5%); cancer in 11 (5%); surgical complications in 5 (2%); disease recurrence in 13 (6%); respiratory failure in 5 (2%); and unknown in 84 (36%).

Survival to one postoperative year and to the end of follow-up was not associated with anaemia (Fig. 1), but was associated with a number of variables (Tables 2 and 3). Pre-operative anaemia was associated with increased peri-operative events, OR (95%CI): 1.70 (0.82–2.59) for intra-operative red blood cell transfusion,  $p < 0.001$ ; and OR (95%CI) 1.72 (1.11–2.67) for acute post-operative kidney injury,  $p < 0.001$ . Pre-operative anaemia showed association with renal replacement therapy; OR (95%CI) 1.87 (1.11–3.15),  $p = 0.018$  in univariate analysis; however, when correcting for confounding factors, for instance the MELD score, this association did not remain significant. Anaemia was not associated with early allograft dysfunction and surgical complications, OR (95% CI) 1.40 (0.87–2.24) and 1.47 (0.88–2.47),  $p = 0.16$  and  $p = 0.14$ , respectively.

**Table 2** The association of variables with survival to 1 year after orthotopic liver transplantation for 599 patients.

Variables	Univariable model			Multivariable model		
	OR	95%CI	p value	OR	95%CI	p value
Pre-operative						
Anaemia grade						
Any	1.04	0.64–1.68	0.88			
Mild	1.09	0.62–1.94	0.76			
Moderate	1.00	0.59–1.70	0.99			
Severe	1.00	0.39–2.54	> 0.99			
Haemoglobin	0.99	0.90–1.10	0.87			
Age; years	0.98	0.96–1.00	0.087			
Sex; male	0.97	0.61–1.54	0.90			
Body mass index; $\text{kg}^{-1} \cdot \text{m}^2$	0.99	0.94–1.04	0.61			
MELD score	0.95	0.93–0.98	0.001			
Coronary artery disease	1.50	0.43–5.24	0.52			
COPD	1.62	0.61–4.26	0.33			
Diabetes mellitus	0.89	0.54–1.45	0.63			
Hospitalisation	0.52	0.28–0.98	0.043			
Intra-operative						
Cold ischaemia time; $\text{min}^{-1}$	1.00	1.00–1.00	0.43			
Warm ischaemia time; $\text{min}^{-1}$	1.00	0.98–1.01	0.38			
Transfusion						
Packed red blood cells	0.91	0.87–0.95	< 0.001	0.95	0.91–0.99	0.027
Fresh frozen plasma	0.96	0.94–0.99	0.002			
Platelets	0.72	0.58–0.88	0.001			
Postoperative						
Surgical complications	0.26	0.16–0.41	< 0.001	0.42	0.25–0.70	0.001
Early allograft dysfunction	0.48	0.30–0.75	0.001			
Acute kidney injury	0.63	0.39–1.01	0.055			
Renal replacement therapy	0.22	0.14–0.34	< 0.001	0.35	0.21–0.58	< 0.001
Year liver transplantation	0.96	0.91–1.02	0.16			

COPD, chronic obstructive pulmonary disease; MELD, model for end-stage liver disease; OR, odds ratio; CI, confidence interval.

**Table 3** The association of variables with survival to the end of follow-up after orthotopic liver transplantation for 599 patients.

Variables	Univariable model			Multivariable model		
	HR	95%CI	p value	HR	95%CI	p value
Pre-operative						
Anaemia grade						
Any	1.21	0.91–1.62	0.20			
Mild	1.15	0.81–1.62	0.43			
Moderate	1.30	0.94–1.80	0.11			
Severe	0.96	0.54–1.68	0.88			
Haemoglobin	0.96	0.90–1.02	0.22			
Age; years	0.97	0.96–0.99	< 0.001	0.98	0.96–0.99	0.001
Sex; male	0.78	0.58–1.05	0.10			
Body mass index; kg <sup>-1</sup> .m <sup>2</sup>	0.99	0.96–1.02	0.56			
MELD score	0.98	0.97–1.00	0.071			
Coronary artery disease	0.79	0.43–1.45	0.52			
COPD	0.81	0.49–1.32	0.40			
Diabetes mellitus	0.70	0.53–0.94	0.017	0.71	0.53–0.96	0.025
Hospitalisation	0.91	0.59–1.42	0.69			
Intra-operative						
Cold ischaemia time; min <sup>-1</sup>	1.00	1.00–1.00	0.17			
Warm ischaemia time; min <sup>-1</sup>	1.00	0.99–1.01	0.48			
Transfusion						
Packed red blood cells	0.95	0.92–0.97	< 0.001			
Fresh frozen plasma	0.98	0.96–0.99	0.003			
Platelets	0.84	0.76–0.93	0.001			
Postoperative						
Surgical complications	0.49	0.37–0.66	< 0.001	0.62	0.45–0.86	0.004
Early allograft dysfunction	0.72	0.54–0.96	0.025			
Acute kidney injury	0.84	0.64–1.12	0.23			
Renal replacement therapy	0.44	0.33–0.58	< 0.001	0.50	0.37–0.68	< 0.001
Year liver transplantation	0.98	0.94–1.01	0.23			

COPD, chronic obstructive pulmonary disease; MELD, model for end-stage liver disease; HR, hazard ratio; CI, Confidence interval.

## Discussion

We found that pre-operative anaemia was not associated with survival after liver transplantation. Pre-operative anaemia was associated with peri-operative blood transfusion and postoperative acute kidney injury.

Pre-operative anaemia is associated with worse outcome after major cardiac and non-cardiac surgery [7, 14, 22]. Some previous studies have reported an association of pre-operative anaemia with survival after liver transplantation [10], while others have not [6]. Pre-operative anaemia may be indirectly associated with survival after liver transplantation, as survival is worse after blood transfusion [16, 17, 23]. The decision to transfuse blood is affected by variables such as the MELD score or cold ischaemia time, which are associated with impaired coagulation, as well as haemoglobin concentration. Thus, the univariate association

of the MELD score with survival to one postoperative year in our cohort is consistent with its association with coagulation.

Pre-operative anaemia was associated with acute postoperative kidney injury in our cohort. We assume that pre-operative anaemia was also associated with renal replacement therapy, with which anaemia was associated in isolation from other variables. Other studies have reported contradictory evidence for association of anaemia with renal replacement therapy after liver transplantation, which in turn is associated with worse survival [2, 6, 24].

Acute and chronic gastro-intestinal haemorrhage, malnutrition, iron deficiency, folate or vitamin B12 deficiency and suppression of bone marrow are mainly responsible for anaemia in end-stage liver disease patients [9, 25–28]. Increasing pre-operative haemoglobin

concentrations reduces peri-operative blood transfusion after gynaecological, obstetric, oncologic, orthopaedic and abdominal surgery [29–32]. We think that patients awaiting liver transplantation might benefit from pre-operative iron supplementation, which needs to be investigated in prospective randomised studies.

Unfortunately, due to insufficient diagnostic data, the cause of anaemia remains unknown in most of our patients. Iron status was only available for approximately half the study population. Further limitations of our study are the retrospective and monocentric design, which might limit the generalisability of our results. We analysed survival after operations that spanned 12 years, during which medical interventions have changed – such as the use of hydroxyethyl starch – as has general population survival, but date of surgery was not associated with observed survival in our cohort [33, 34].

In conclusion, pre-operative anaemia was not associated with survival after liver transplantation. However, anaemia was associated with blood transfusion, postoperative acute kidney injury and renal replacement therapy.

## Acknowledgements

DB has received honoraria and funding for an investigator-initiated trial from Vifor Pharma. No other external funding or competing interests declared.

## References

- Hoehn RS, Singhal A, Wima K, et al. Effect of pretransplant diabetes on short-term outcomes after liver transplantation: a national cohort study. *Liver International* 2015; **35**: 1902–9.
- Hilmi IA, Damian D, Al-Khafaji A, et al. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. *British Journal of Anaesthesia* 2015; **114**: 919–26.
- Barri YM, Sanchez EQ, Jennings LW, et al. Acute kidney injury following liver transplantation: definition and outcome. *Liver Transplantation* 2009; **15**: 475–83.
- Zand MS, Orloff MS, Abt P, et al. High mortality in orthotopic liver transplant recipients who require hemodialysis. *Clinical Transplantation* 2011; **25**: 213–21.
- Pungpapong S, Alvarez S, Hellinger WC, et al. Peritonitis after liver transplantation: incidence, risk factors, microbiology profiles, and outcome. *Liver Transplantation* 2006; **12**: 1244–52.
- Collas O, Robertson FP, Fuller BJ, Davidson BR. Anaemia in patients with chronic liver disease and its association with morbidity and mortality following liver transplantation. *International Journal of Surgery* 2018; **53**: 48–52.
- Baron DM, Hochrieser H, Posch M, et al. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. *British Journal of Anaesthesia* 2014; **113**: 416–23.
- Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. *Lancet* 2011; **378**: 1396–407.
- Gonzalez-Casas R, Jones EA, Moreno-Otero R. Spectrum of anemia associated with chronic liver disease. *World Journal of Gastroenterology* 2009; **15**: 4653–8.
- Badawy A, Kaido T, Hammad A, et al. The impact of preoperative hemoglobin level on the short-term outcomes after living donor liver transplantation. *World Journal of Surgery* 2018; **42**: 4081–9.
- Gombotz H, Hofmann A. Patient blood management: three pillar strategy to improve outcome through avoidance of allogeneic blood products. *Der Anaesthetist* 2013; **62**: 519–27.
- Muñoz M, Gómez-Ramírez S, Kozek-Langenecker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. *British Journal of Anaesthesia* 2015; **115**: 15–24.
- Haase M, Bellomo R, Story D, et al. Effect of mean arterial pressure, haemoglobin and blood transfusion during cardiopulmonary bypass on post-operative acute kidney injury. *Nephrology Dialysis Transplantation* 2012; **27**: 153–60.
- LaPar DJ, Hawkins RB, McMurry TL, et al. Preoperative anemia versus blood transfusion: which is the culprit for worse outcomes in cardiac surgery? *Journal of Thoracic and Cardiovascular Surgery* 2018; **156**: 66–74.
- Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB. Intraoperative transfusion of 1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, pneumonia, and sepsis in general surgery patients. *Journal of the American College of Surgeons* 2009; **208**: 931–7.
- Glance LG, Dick AW, Mukamel DB, et al. Association between intraoperative blood transfusion and mortality and morbidity in patients undergoing noncardiac surgery. *Anesthesiology* 2011; **114**: 283–92.
- de Boer MT, Christensen MC, Asmussen M, et al. The impact of intraoperative transfusion of platelets and red blood cells on survival after liver transplantation. *Anesthesia and Analgesia* 2008; **106**: 32–44.
- World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. 2011. <http://www.who.int/vmnis/indicators/haemoglobin.pdf>. <http://www.who.int/vmnis/indicators/haemoglobin.pdf> (accessed 17/10/2018).
- Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. *Liver Transplantation* 2010; **16**: 943–9.
- Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: part 1: definitions, conservative management and contrast-induced nephropathy. *Nephrology Dialysis Transplantation* 2012; **27**: 4263–72.
- Core R, Team R. *A language and environment for statistical computing*. Vienna, Austria: R Foundation For Statistical Computing, 2019.
- Hung M, Besser M, Sharples LD, Nair SK, Klein AA. The prevalence and association with transfusion, intensive care unit stay and mortality of pre-operative anaemia in a cohort of cardiac surgery patients. *Anaesthesia* 2011; **66**: 812–18.
- Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. *New England Journal of Medicine* 2011; **365**: 2453–62.
- Biteker M, Dayan A, Tekkeşin Aİ, et al. Incidence, risk factors, and outcomes of perioperative acute kidney injury in noncardiac and nonvascular surgery. *American Journal of Surgery* 2014; **207**: 53–9.

25. Stein J, Connor S, Virgin G, Ong DE, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. *World Journal of Gastroenterology* 2016; **22**: 7908–25.
26. Mahamid M, Mahroum N, Bragazzi N, et al. Folate and B12 levels correlate with histological severity in NASH patients. *Nutrients* 2018; **10**: E440.
27. Villanueva C, Aracil C, Colomo A, et al. Acute hemodynamic response to  $\beta$ -blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. *Gastroenterology* 2009; **137**: 119–28.
28. Bihari C, Anand L, Rooge S, et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. *Hepatology* 2016; **64**: 1273–88.
29. Ellermann I, Bueckmann A, Eveslage M, et al. Treating anemia in the preanesthesia assessment clinic: results of a retrospective evaluation. *Anesthesia and Analgesia* 2018; **127**: 1202–10.
30. Keding V, Zacharowski K, Bechstein WO, Meybohm P, Schnitzbauer AA. Patient blood management improves outcome in oncologic surgery. *World Journal of Surgical Oncology* 2018; **16**: 159.
31. Gupta PB, DeMario VM, Amin RM, et al. Patient blood management program improves blood use and clinical outcomes in orthopedic surgery. *Anesthesiology* 2018; **129**: 1082–91.
32. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. *Annals of Surgery* 2016; **264**: 41–6.
33. Massicotte L, Lenis S, Thibeault L, Sassine M-P, Seal RF, Roy A. Effect of low central venous pressure and phlebotomy on blood product transfusion requirements during liver transplantations. *Liver Transplantation* 2006; **12**: 117–23.
34. Schroeder RA, Collins BH, Tuttle-Newhall E, et al. Intraoperative fluid management during orthotopic liver transplantation. *Journal of Cardiothoracic and Vascular Anesthesia* 2004; **18**: 438–41.

## Supporting Information

Additional supporting information may be found online via the journal website.

**Table S1.** Prevalence of anaemia according to the aetiology of liver disease.